



The Digital Examiner
www.prostaaid.org

"Issue #308" October 2025



Guest Speaker October 15
Introduction to PARP-Inhibitors and Their Role in
Cancer Treatment



Dr. Tarek Bismar

Dr. Tarek Bismar carried out his medical education in Syria at Damascus University faculty of Medicine graduating in 1996. He then moved to USA to continue his career where he worked as Research assistant at Michigan State University. In 2000, Dr. Bismar joined Washington University St. Louis for his Pathology residency in Anatomical pathology, followed by surgical pathology fellowship at Wayne State University in 2002 and a GU pathology fellowship at Harvard Medical School in 2003. In 2004, he joined the faculty of Medicine at McGill University as assistant professor and was appointed as the director of the Pathology Core Facility in 2005. In 2008 he moved to University of Calgary Cumming School of Medicine as associate professor and in 2015 he was promoted to full professor. Dr. Bismar directs a research lab is focusing on characterizing novel genetic signatures for GU cancers.

Dr. Bismar has published more than 115 peer reviewed publications mostly in prostate cancer biomarkers and genomic signatures and currently has active collaborations with several national and international investigators. His research employ multiple platforms including gene expression, copy number alteration and whole exome/genome sequencing of somatic and germ line mutations in association to invitro/in-vivo manipulation.

Tailgating With Dr. Digital 2025



Starting July 16th, our progressive 50/50 raffle will run each month and the final draw will be held at our 2025 Pathfinder Award event on

December 3.
Pool Total To Date Is \$340



This will be a 6 month consecutive sale of tickets at all of our General meetings. You must buy a ticket in person at one or all of these meetings. All tickets sold will be recorded so that if for any reason you are unable to attend the final draw, you will still be eligible. We will have an electronic paying option as well as cash. The ticket price is 1 for \$5 or 3 for \$10.

THERE WILL BE NO ONLINE SALES AT ALL ONLY IN PERSON SALES AND ALL SALES ARE FINAL

AGLC Licence# 733539



Warriors Lunch

Reminder to all of our Warriors that our next pizza lunch at Bella Roma Pizza in Lakeview is scheduled for **Tuesday October 7th starting at 11:30 am.**

Confirm your attendance and don't forget to bring \$20 to help cover the cost.

[RSVP jim.richardson@telus.net](mailto:jim.richardson@telus.net)

Bella Roma Pizza #17 6449 Crowchild Tr. SW.

All of our monthly General meetings are held on the third Wednesday of every month

Location for in person is:

CKE Community Centre (1015 73 Ave SW, Calgary, AB)

If you are unable to attend in person

Sign up [HERE](#) to join us online

Warriors & Wives Partners and Caregivers

Join us on Wednesday, October 15th.

We are meeting at CKE

**Starting at 6:00 pm for both the warriors and wives,
partners and caregivers in their designated areas.**

**We then will meet at 7 pm in the main hall for our
social gathering.**

**At 7:30 pm we will start our general meeting with our
guest speaker.**



***Do you have this much free time a month?
Looking for something new to do?
We're looking for new directors.
That's all we're asking for is 5 hours a month.
If interested let us know.
[Email us at info@prostaaid.org](mailto:info@prostaaid.org)***



Donate Today

PROSTATAID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

[Donate Today](#)

Connect With Us

Information
Phone 403 455 1916
info@prostaaid.org
Brad Sterling
President
president@prostaaid.org

[Connect With Us](#)

Support Groups

Jim Richardson
Warriors
jim.richardson@telus.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaaid.org

[Meeting Info Here](#)

Articles Of Interest




DRIVING CHANGE FOR MEN'S HEALTH

The MAN VAN® is Canada's first and only mobile men's health clinic offering FREE PSA (Prostate Specific Antigen) blood testing used for early detection of prostate cancer.

Now serving Edmonton & north for men 50 to 70 years of age

- No appointment necessary
- Testing ages 40 to 70
- Find the next community clinic near you
- 15 minutes can save your life!

[MAN VAN UPCOMING CLINICS](#)




Carotuximab plus apalutamide demonstrates promising PFS in mCRPC

The combination of carotuximab (ENV105) plus apalutamide (Erleada) demonstrated encouraging progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors had progressed following standard hormone-based therapies, according to an interim efficacy analysis of a phase 2 trial

Trial info

September 2025
Urology Times

Carotuximab




The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer

Multiple systemic treatments are available for metastatic castration-resistant prostate cancer (mCRPC), with unclear safety profiles. This study seeks to describe the safety determined in randomized clinical trials of a systemic treatment for mCRPC and whether safety differs by age.

Trial Info

URO Today
September 2025

Abiraterone



Molecular test helps tailor chemotherapy for advanced prostate cancer patients

The study included 1,523 patients recruited to the STAMPEDE phase III trials, that had been diagnosed with advanced prostate cancer and started treatment with androgen deprivation therapy (ADT), which blocks male hormones such as testosterone that can drive prostate cancer growth. The STAMPEDE trials tested the additional benefit of adding abiraterone or docetaxel to ADT and the study patients were followed up for a median of 14 years.

Study Overview

August 2025
Oncology & Cancer

Molecular



Diode laser enucleation prostate for benign prostatic hyperplasia: outcomes of the Leonardi ejaculation sparing technique.

Benign prostatic hyperplasia (BPH) significantly impairs quality of life and may lead to complications such as urinary retention and recurrent infections. While endoscopic enucleation techniques provide effective relief, they are frequently associated with loss of antegrade ejaculation. The Leonardi Ejaculation-Sparing Technique (LEST) was developed to preserve ejaculatory function during diode laser enucleation of the prostate (DILEP).

Trial Info

September 2025
Renal+Urology

BPH Laser




Trial Proves Biparametric MRI Is Accurate for Prostate Cancer Diagnosis

Biparametric MRI performs as well as multiparametric MRI for diagnosis of clinically significant prostate cancer, according to results from the Prostate Imaging using MRI \pm Contrast Enhancement (PRIME) trial published in *JAMA*. Using biparametric MRI can reduce MRI scan time from approximately 40 minutes to 20 minutes, leading to more efficient scan use, less toxicity from contrast, and possibly quicker prostate cancer diagnoses.

[More Info Here](#)

September 2025
Renal+Urology

Biparametric



Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy

Radical prostatectomy (RP) is a common treatment for men with localized prostate cancer (PC), but its impact on survival remains uncertain. Pelvic lymph node dissection (PLND) during RP has become standard, especially for high-risk patients with lymph node involvement (LNI). Patients with pN1 PC, or lymph node-positive prostate cancer after RP, often need additional treatment to reduce cancer recurrence risk.

[More Info](#)

August 2025
Urology Times

Lymph Node




FDA greenlights phase 1 trial of alpha radioligand therapy in mCRPC

The FDA has granted clearance to an investigational new drug (IND) application for the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy AB001, thus enabling the launch of a phase 1 trial of the agent in patients with metastatic castration-resistant prostate cancer (mCRPC), ARTBIO announced in a news release.¹

AB001 is a novel PSMA-targeted and Pb212-based radioligand therapy designed to treat patients with metastatic prostate cancer, one that we believe has the potential to increase the radioligand dose rate to tumors without higher toxicity to normal tissues

September 2025
Urology Times

AB001



Pre-existing Depression Linked to Lower Survival Among Patients With Prostate Cancer

Approximately 1 in 6 prostate cancer patients experiences major depression, a prevalence twice as high as the general population, Lei Zhang, MD, of the Uniformed Services University of the Health Sciences, Bethesda, Maryland, and colleagues pointed out. Using data from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Zhang's team studied survival among 38,169 health care patients, of whom 205 (0.6%) had prostate cancer and depression (mean age, 61 years).

Trial Info

September 2025
Renal + Urology

Depression

Canadian Prostate Cancer Guide

Resources, guides and tools to help caregivers, survivors and the recently diagnosed get clarity and more. Read empowering stories and share yours with us.

Bringing you the most up to date information in treatments, support, well-being, and more all in one place

We can help you in achieving the support you're looking for. On the Canadian Prostate Cancer Guide website you can look to find the most up to date information on prostate cancer in one place.

[Learn More Here](#)

Read about these articles below

- 1-Significant Phase III Oncology Trials
- 2- FDA approves 3-month formulation of leuprolide mesylate
- 3-How to keep your prostate healthy
- 4-Hydrogen sulfide prodrug SG1002 protects against erectile dysfunction
- 5-Academy event trained patients to be experts
- 6-Survival Gains Slowing in the United States
- 7-2025 PCRI Men's Health Conference Video
- 8-ClarityDX

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



Articles For Everyone



Reproducibility of Statistically Significant Phase III Oncology Trials

Phase III randomized trials are the gold standard for evaluating comparative efficacy and require considerable resources. In other fields of clinical medicine, it is common for regulatory approvals to be granted only after at least two phase 3 trials have shown comparative efficacy for the new treatment.

September 2025
URO Today

Phase 3 Trials



FDA approves 3-month formulation of leuprolide mesylate for advanced prostate cancer

The approval is supported by findings from an open-label, single-arm, phase 3 trial (NCT03261999) of leuprolide mesylate administered as 2 injections, 3 months apart in patients with advanced prostate cancer. Overall, the study met its primary end point with 97.9% of patients achieving a serum testosterone concentration suppression to castrate levels (≤ 50 ng/dL) from day 28 through day 168.

August 2025
Urology Times

Leuprolide



How to keep your prostate healthy and lower your risk of developing serious problems

For something so small, the prostate can cause big problems. This gland, which is roughly the size of a walnut, is an essential part of a man's urinary and reproductive systems.

But it's not uncommon for men to suffer from prostate-related issues, especially as they age. In fact, age is one of the biggest risk factors for some conditions, including an enlarged prostate and prostate cancer.

[More Info](#)

September 2025
MedicaXpress

Healthy



Chronic administration of the hydrogen sulfide prodrug SG1002 partially protects against erectile dysfunction resulting from long-term androgen deprivation.

Androgen deprivation therapy is a common treatment strategy for prostate cancer, although erectile dysfunction (ED) often coincides as an undesirable side-effect. Hydrogen sulfide (H₂S) is an endogenous gasotransmitter with vasodilatory, anti-inflammatory, and antioxidant-like properties. H₂S therapies are being developed for cardiovascular disease management, although the properties of H₂S may also protect the erectile system.

[More Info Here](#)

September 2025
URO Today

ED




Academy event trained patients to be experts

“It was an intense but inspiring experience that gave me a deep sense of connection,” said one of the participants, Karl Mortier from the Belgian prostate cancer patients’ organisation Wij Ook. “We spoke openly about our experiences and about the importance of communication and breaking the taboo surrounding prostate cancer.”

[Read more here](#)

September 2025
Europa

Trained



Prostate Cancer Stage Increasing, Survival Gains Slowing in the United States

A *Prostate Cancer Statistics 2025* report from the American Cancer Society (ACS) shows that new cases of prostate cancer in the US are rising 3.0% annually from 2014 to 2021, reversing the annual 6.4% declines enjoyed from 2007 to 2014. Advanced-stage diagnoses are rising even faster at 4.6% to 4.8% per year. Meanwhile, mortality declines among men with prostate cancer have slowed from 3% to 4% annually around the millennium to a mere 0.6% annually in the most recent decade.

September 2025
Renal + Urology

Stages




2025 PCRI Men's Health Conference

Topics will include general men's health, annual lab tests, cardiovascular health, sleep & cancer, insurance & AI, diet, and exercise. Each topic will be presented by expert physicians immediately, followed by in-depth question and answer sessions.

September 2025
PCRI

2025 Conference



ClarityDX technology can be used to predict the risk of disease.

When it comes to a cancer diagnosis, Clarity means peace of mind. And when it comes to prostate cancer detection, it takes the right data to deliver that Clarity.

ClarityDX Prostate is a clinically proven decision support tool that uses a machine learning platform to calculate an accurate prostate cancer risk score from clinical data and multiple blood-based PSA test results (5-7).

If you have an elevated PSA, or a suspicion of prostate cancer, ClarityDX Prostate may be right for you. ClarityDX Prostate takes the fear and uncertainty out of prostate cancer screening.

ClarityDX

Thank you to our Sponsors and Community Partners



Disclaimer: The PROSTAID Calgary Society website & newsletter provides news and information about prostate issues and activities of the organization. While information is presented about prostate cancer and related issues, it is not intended as a substitute for professional medical advice, diagnosis, or treatment. PROSTAID Calgary Society recommends that you seek the advice of your physician or other qualified health professionals regarding questions you may have about any medical condition. Topics on PROSTAID Calgary Society's website & newsletter are presented to inform you and we encourage you to seek professional medical advice before starting any treatment.

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



[Unsubscribe](#)